fda approval

4+ articles

AI Bryan Johnson Christmas Elon Musk GLP-1 drugs

Elon Musk's Ally Antonio Gracias Eyes Major Role in Psychedelic Medicine with Lykos Therapeutics Takeover

Antonio Gracias, a close ally of Elon Musk, is in the spotlight with a bid to take over Lykos Therapeutics—a move potentially worth $100 million. Backed by major investors including Sir Christopher Hohn, the acquisition aims to reshape the future of MDMA-assisted therapies, bringing management shakeups and sparking debates on drug policy and approval processes. This pivotal development highlights the increasing financial interest in the psychedelic medicine industry.

Aug 28

Elon Musk's Ally Antonio Gracias Eyes Major Role in Psychedelic Medicine with Lykos Therapeutics Takeover

Craif Secures $22M to Revolutionize Early Cancer Detection with AI-Powered miRNA Tech

Japanese startup Craif is making waves as it secures $22 million in Series C funding to bring its groundbreaking AI-driven cancer detection platform to the U.S. market. Using microRNA (miRNA) from urine, Craif's miSignal test offers a non-invasive alternative to traditional methods, aiming to detect seven types of cancer early on. With plans to expand detection capabilities and explore other applications, this innovative platform is on track for U.S. trials by 2029, with FDA approval on the horizon.

Apr 28

Craif Secures $22M to Revolutionize Early Cancer Detection with AI-Powered miRNA Tech

Bryan Johnson's Dramatic Rapamycin Exit: A Wake-Up Call for the Anti-Aging Industry!

Tech titan and biohacking fanatic, Bryan Johnson calls it quits on his 5-year rapamycin regimen due to side effects. What does this mean for the anti-aging world? We dive into the potential risks, scientific skepticism, and what the future holds for longevity research.

Jan 17

Bryan Johnson's Dramatic Rapamycin Exit: A Wake-Up Call for the Anti-Aging Industry!

Elon Musk Celebrates the Holidays as ‘Ozempic Santa’, Sparking Weight Loss Conversations!

In a festive twist, Elon Musk revealed he's taking the weight-loss drug Mounjaro while clad in a Santa suit he dubbed 'Ozempic Santa.' This merry disclosure not only played on Ozempic’s catchy name but also kickstarted debates on the rising trend of GLP-1 medications for weight management. As these drugs gain traction, it’s a reminder of the blend of technology, health, and quirky humor Musk often brings to the table.

Dec 27

Elon Musk Celebrates the Holidays as ‘Ozempic Santa’, Sparking Weight Loss Conversations!

Loading news...